ProCE Banner Series

Refining Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma: Expert Guidance on Bispecific Antibody Therapy Optimization

Engage with expert faculty as they provide a comprehensive overview of bispecific antibodies in relapsed/refractory multiple myeloma, including clinical considerations, common toxicities, and prophylaxis and management strategies. 

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

The target audience for this program includes hematologists/oncologists, oncology nurses, oncology NPs/PAs, oncology pharmacists, emergency physicians, neurologists, and infectious disease physicians caring for patients with R/R MM.

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, confidence, competence, and practice change in optimizing treatment with bispecific antibodies (BsAbs) for patients with relapsed/refractory multiple myeloma (R/R MM).

Target Audience
The target audience for this program includes hematologists/oncologists, oncology nurses, oncology NPs/PAs, oncology pharmacists, emergency physicians, neurologists, and infectious disease physicians caring for patients with R/R MM.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Analyze the criteria for R/R MM diagnosis and the subsequent process for timely referral to specialists, emphasizing the importance of early intervention.

  • Demonstrate proficiency in the handling, administration, and transitioning care of BsAbs from inpatient to outpatient settings, ensuring continuity of care.

  • Evaluate the available clinical data on BsAbs, interpreting insights into their efficacy, appropriate dosing, and adverse events (AEs) profiles for informed decision-making.

  • Identify the key risk factors associated with treatment-specific AEs related to BsAbs, and formulate evidence-based strategies for timely identification and effective management.

  • Advocate for equity in R/R MM treatment by recognizing disparities in care, highlighting experiences with BsAbs, and promoting strategies that ensure equitable access to treatment for diverse and underrepresented patient populations.

Accreditation

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-25-001-L01-P

Type of activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.